Irpagratinib

依帕戈替尼

Report date: 2026/04/02 10:52:46
NME

Base Information

Drug NameIrpagratinib
Drug Alias NameABSK-011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanSouth Korea +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesABbisko Therapeutics Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesABbisko Therapeutics Co LtdRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A